Telomir Pharmaceuticals Unveils Promising Preclinical Data for Telomir-1

Telomir Pharmaceuticals has reported promising preclinical findings for its lead candidate, Telomir-1. The data reveals Telomir-1’s impact on the CASP8 and GSTP1 genes, central to cancer protection mechanisms. In an in vivo study, mice with aggressive prostate cancer received Telomir-1, showing significant modulation in DNA methylation for these genes, associated with cancer progression.

CASP8 is integral in apoptosis, or programmed cell death, while GSTP1 is involved in detoxification. The study suggests Telomir-1 reduces methylation more effectively than chemotherapy, potentially reversing gene silencing. Notably, Telomir-1's effect was more sustained compared to Rapamycin, which only temporarily reduced methylation.

The findings underscore the potential for Telomir-1 to engage critical pathways in cancer biology. Future studies aim to further elucidate these mechanisms, enhancing understanding of Telomir-1’s impact on cancer treatment.